Omnicell, Inc. (OMCL) VP Sells $1,056,254.62 in Stock
Omnicell, Inc. (NASDAQ:OMCL) VP Jorge R. Taborga sold 20,719 shares of the stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $50.98, for a total transaction of $1,056,254.62. Following the completion of the sale, the vice president now owns 53,270 shares in the company, valued at $2,715,704.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of Omnicell, Inc. (NASDAQ:OMCL) traded down 1.17% during mid-day trading on Tuesday, reaching $50.85. 209,491 shares of the company’s stock traded hands. The company has a 50 day moving average of $44.33 and a 200 day moving average of $40.56. Omnicell, Inc. has a 12 month low of $30.35 and a 12 month high of $51.97. The company’s market cap is $1.89 billion.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.02. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The firm had revenue of $180.90 million for the quarter, compared to analyst estimates of $174.08 million. During the same period in the previous year, the firm earned $0.38 earnings per share. The company’s revenue was up 4.6% compared to the same quarter last year. Analysts expect that Omnicell, Inc. will post $1.31 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Omnicell, Inc. (OMCL) VP Sells $1,056,254.62 in Stock” was reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/08/08/omnicell-inc-omcl-vp-sells-1056254-62-in-stock.html.
A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. raised its position in shares of Omnicell by 139,475.2% in the first quarter. BlackRock Inc. now owns 4,487,343 shares of the company’s stock valued at $182,412,000 after buying an additional 4,484,128 shares during the period. Eagle Asset Management Inc. raised its position in shares of Omnicell by 580.1% in the first quarter. Eagle Asset Management Inc. now owns 793,649 shares of the company’s stock valued at $32,261,000 after buying an additional 676,955 shares during the period. Principal Financial Group Inc. raised its position in shares of Omnicell by 124.9% in the second quarter. Principal Financial Group Inc. now owns 660,803 shares of the company’s stock valued at $28,481,000 after buying an additional 367,019 shares during the period. Norges Bank acquired a new position in shares of Omnicell during the fourth quarter valued at about $10,913,000. Finally, Wells Fargo & Company MN raised its position in shares of Omnicell by 99.6% in the first quarter. Wells Fargo & Company MN now owns 561,295 shares of the company’s stock valued at $22,817,000 after buying an additional 280,017 shares during the period. 96.35% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages recently weighed in on OMCL. BidaskClub downgraded shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Piper Jaffray Companies restated a “hold” rating and set a $40.00 target price on shares of Omnicell in a report on Sunday, July 30th. Dougherty & Co raised their target price on shares of Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Craig Hallum raised their target price on shares of Omnicell from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $47.00 target price on shares of Omnicell in a report on Tuesday, July 25th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Omnicell currently has an average rating of “Buy” and an average price target of $49.00.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.